The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
Janus Henderson Global Life Sciences T JAGLX
- NAV / 1-Day Return 78.79 / +0.28 %
- Total Assets 5.9 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.920%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.06%
- Turnover 34%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:53 PM GMT+0
Morningstar’s Analysis JAGLX
Will JAGLX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 8.12 | 458.5 Mil | Healthcare |
UnitedHealth Group Inc | 6.90 | 389.9 Mil | Healthcare |
Novo Nordisk AS Class B | 5.45 | 308.1 Mil | Healthcare |
AbbVie Inc | 3.87 | 218.7 Mil | Healthcare |
AstraZeneca PLC | 3.84 | 216.8 Mil | Healthcare |
Amgen Inc | 3.29 | 186.0 Mil | Healthcare |
Merck & Co Inc | 2.95 | 166.7 Mil | Healthcare |
Sanofi SA | 2.55 | 144.3 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.44 | 137.8 Mil | Healthcare |
Boston Scientific Corp | 2.34 | 132.4 Mil | Healthcare |